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Withaferin-A kills cancer cells with and without
telomerase: chemical, computational and experimental
evidences
Yue Yu1,2, Shashank P Katiyar3, Durai Sundar3, Zeenia Kaul4,5, Eijiro Miyako6, Zhenya Zhang2, Sunil C Kaul*,1, Roger R Reddel4 and
Renu Wadhwa*,1
Maintenance of telomere length is the most consistent attribute of cancer cells. Tightly connected to their capacity to overcome
replicative mortality, it is achieved either by activation of telomerase or an Alternative mechanism of Lengthening of Telomeres
(ALT). Disruption of either of these mechanisms has been shown to induce DNA damage signalling leading to senescence or
apoptosis. Telomerase inhibitors are considered as potential anticancer drugs but are ineffective for ALT cancers (~15% of all
cancers). Withaferin-A (Wi-A), a major constituent of the medicinal plant, Withania somnifera (Ashwagandha), has been shown to
exert anti-tumour activity. However, its effect on either telomerase or ALT mechanisms has not been investigated. Here, by using
isogenic cancer cells with/without telomerase, we found that Wi-A caused stronger cytotoxicity to ALT cells. It was associated with
inhibition of ALT-associated promyelocytic leukemia nuclear bodies, an established marker of ALT. Comparative analyses of
telomerase positive and ALT cells revealed that Wi-A caused stronger telomere dysfunction and upregulation of DNA damage
response in ALT cells. Molecular computational and experimental analyses revealed that Wi-A led to Myc-Mad mediated
transcriptional suppression of NBS-1, an MRN complex protein that is an essential component of the ALT mechanism. The results
suggest that Wi-A could be a new candidate drug for ALT cancers.
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Normal somatic cells have a finite life span that is regulated by
tumour suppressor mechanisms and shortening of telomeres.
Cancer cells circumvent telomere shortening by activation of
telomerase, a ribonucleoprotein consisting of RNA (TR) and
reverse transcriptase enzyme (TERT) component, which adds
TTAGGG to telomeric ends. Ectopic expression of hTERT in
normal human fibroblasts has been shown to induce elonga-
tion of telomeres, permanent cell proliferation and suscept-
ibility to experimental transformation.1,2 In contrast to the
upregulation of telomerase in large majority of cancer cells,
telomerase-negative cancer cells possess mechanisms
referred to as ALT (Alternate Lengthening of Telomeres).3
ALT cells are characterized by very heterogeneous telomeres
and possess large nuclear structures (ALT-associated Pro-
myelocytic Leukemia (PML) Body) called APB that contain
telomeric DNA and several proteins including PML, TRF1,
TRF2, Replication factor A, RAD51 and RAD52.4–7 Recon-
stitution of telomerase activity in ALT cells has revealed that
the human cells are capable of utilizing telomerase-dependent
and -independent mechanisms of telomere maintenance
concomitantly.8,9 ALT has been detected not only in cultured
cancer cells but also in tumour tissues accounting for 10–15%
of all cancers, with high prevalence (≥ 20%) of liposarcoma,
epithelioid sarcoma, chondrosarcoma, astrocytoma,
malignant fibrous histiocytoma, glioblastoma multiforme,
gastric carcinoma and neuroblastoma.10–12
The MRE11-RAD50-NBS1 (MRN) protein complex acts as
a DNA damage sensor and controls DNA repair, cell cycle,
telomere maintenance and genome stability by regulation of
ATM (ataxia-telangiectasia mutated), ATR (ataxia-telangiecta-
sia and Rad-3-related) and DNA PKcs (DNA protein kinase
catalytic subunit) activities.13–15 MRN is essential for timely
activation of ATM-mediated pathways and its dysfunction
causes genome instability and premature ageing dis-
orders, including ataxia telangiectasia (A-T), A-T-like disorder
(ATLD) and Nijmegen breakage syndrome (NBS).16–18 Over-
expression of NBS1 protein was shown to increase cell
proliferation,19 its knockdown led to hypermutability and
telomere changes that have been related to cancer
predisposition.20 Hypomorphic mutations of the MRE11 gene
lead to ATLD.21 Cells compromised for RAD50 also showed
rapid shortening of chromosome ends and end-to-end
chromosome fusions.22,23 siRNA-mediated depletion of any
subunits of MRN complex led to depletion of other subunits of
the complex suggesting their co-regulation.14 MRN is found in
APBs, and overexpression of Sp100, which caused seques-
tration of MRN proteins away from APBs, resulted in
repression of the ALT mechanism, which was manifested by
telomere length changes and suppression of APB formation,24
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suggesting that MRN is involved in ALT. MRN complex
proteins are regulated by c-Myc and n-Myc cellular
oncogenes.25 Because of high incidence of telomerase
activation in a wide variety of cancers, anti-telomerase drugs
are considered useful for therapy. However, ALT tumours will
be refractory to such drugs, so identification and characteriza-
tion of new anti-ALT molecules is essential.
Withaferin-A (Wi-A) is a steroidal lactone found in the
medicinal plant, Withania somnifera (Ashwagandha). It has
anticancer activity attributable to (i) cell cycle arrest by
downregulation of cyclin B1, cyclin A, Cdk2 and p-Cdc2
expression and increase in the levels of p-Chk1 and p-Chk2,
(ii) downregulation of HPV E6 and E7 oncoproteins,
(iii) induction and accumulation of p53, (iv) increased levels
of p21WAF1, (v) a decrease in the levels of STAT3, (vi) an incre-
ase in p53-mediated apoptotic markers-Bcl2, Bax, caspase-3,
cleaved PARPand Par-4, (vii) downregulation of AKTand EMT
signalling and (viii) disruption of cytoskeleton elements
including actin, vimentin and intermediate filaments suggest-
ing that it is a potential natural anticancer drug.26–29 In the
present study, we investigated the effect of Wi-A on isogenic
telomerase-plus (TEP) and -minus (ALT) cancer cells and
found that it causes a stronger cytotoxicity to ALT cells. We
provide experimental and computational evidences that Wi-A
causes apoptosis in ALT cells by inhibition of ALT phenotype,
induction of telomere dysfunction and Myc-Mad mediated
transcriptional suppression of NBS-1, an MRN complex
protein, an essential component of ALT mechanism.
Results
Wi-A caused stronger cytotoxicity to ALT cells. We used
two pairs of isogenic cells with and without telomerase, to
determine the cytotoxicity in response to Wi-A. As shown in
Figures 1A−C, a dose-dependent cytotoxic response was
observed in all four cell lines (Telomerase Plus, TEP and
telomerase negative, ALT). Of note, ALT (JFCF-1 L and
JFCF-4D) cells showed stronger cytotoxicity at all doses as
compared to the Telomerase Plus (TEP; JFCF-6B and
JFCF-6G) cells. The IC50 values (μg/ml) for 24 and 48 h
treatments were 0.6 and 0.19 (JFCF-4D) and 0.9 and 0.25
(JFCF-1 L) for ALT, and 1.2 and 0.44 (JFCF-6B) and 1.4 and
0.5 (JFCF-6G) for TEP cells, respectively. The results were
confirmed by visual observations; 0.5 and 1 μg/ml of Wi-A
caused apoptosis in ALT, but not TEP, cells (Figure 1d).
Colony forming assays with low dose (0.25 μg/ml) of Wi-A
also revealed its stronger cytotoxicity to ALT cells (Figure 1e).
Furthermore, tumour-derived ALT (U2OS; osteosarcoma)
cells also showed higher cytotoxicity than TEP (MCF7;
breast carcinoma) cells (Supplementary Figure S1A). We
investigated the molecular mechanism of its differential effect
in response to low dose of Wi-A on TEP and ALT cells.
Low dose of Wi-A induced apoptosis in ALT cells. Cell
cycle analysis of control and Wi-A treated cells showed a
significant increase in the number of JFCF-1L (ALT), but not
JFCF-6B (TEP), cells in G2/M phase (Figure 2a). Further-
more, as determined by Annexin V staining, Wi-A treated ALT,
but not TEP, cells showed strong induction of apoptosis
(Figure 2b). Western blotting of proteins critical for apop-
tosis and G2/M transition, we found a marked increase in
the cleaved PARP-1 and PARP-9 (established makers of
apoptosis) in Wi-A treated ALT, but not TEP, cells (Figures 2c
and d); total PARP-1/9 showed decrease. Furthermore,
procaspase-3 decreased in Wi-A treated ALT cells, confirm-
ing apoptosis (Figure 2e).
We next examined the expression of p53, p21 and Cyclin
B1, the key regulators of cell cycle progression. As shown in
Figure 2f, both ALT and TEP cells did not show wild type p53
activity as determined by reporter assay. Western blotting for
p53 revealed its downregulation in Wi-A treated ALT cells only
(Figure 2g). The latter also showed increase in p21 and
decrease in Cyclin B1 (Figure 2g). Taken together, these data
suggested that stronger toxicity of Wi-A to ALT cells is
mediated by induction of G2/M arrest and apoptotic signalling.
Wi-A caused inhibition of ALT phenotype. In order to get
molecular insights to the stronger cytotoxicity of Wi-A to
ALT cells, we examined a well-established marker for ALT,
APBs (ALT-associated PML nuclear bodies). As expected,
APBs (detected here by co-localization of the TRF2 telomeric
binding protein and PML protein) occurred specifically in
ALT cells (Figure 3a). Of note, Wi-A treated ALT cells showed
20−40% reduction in APBs (Figure 3b). On the other hand,
telomerase activity (determined by TRAP assay) in control as
well as Wi-A treated TEP (JFCF-6B, MCF-7 and G361) and
ALT (JFCF-1L and U2OS) cells remained unchanged
(Figure 3c).
Wi-A has been shown to induce DNA damage and oxidative
stress response in cancer cells.30,31We hence anticipated that
the high sensitivity of ALT cells to Wi-A may be due to stronger
induction of DNA damage response. Neutral comet assay to
examine DNA double strand breaks (DSB) directly showed a
marked (twofold) increase in DSB formation in Wi-A treated
ALT cells (Figure 3d). TEP cells treated with equivalent dose
(0.25 μg/ml) of Wi-A showed no difference in DSB content with
respect to the control group (Figure 3d) suggesting that these
cells are somewhat resistant to Wi-A induced DSB. The
induction of DNA breaks after Wi-A treatment was also
examined by γH2AX immunostaining. Whereas TEP cells
showed no difference in γH2AX staining between control and
Wi-A (0.25 μg/ml) treated cells, JFCF-1L cells showed a large
increase in the number of γH2AX positive cells (Figure 3e).
These data were consistent with Comet assay results and
suggested that Wi-A caused stronger DNA damage response
in ALT cells.
Wi-A caused telomere dysfunction in ALT cells. In order
to investigate whether treatment with Wi-A affects telomere
length, we performed qPCR-based telomere length assays in
control and Wi-A treated TEP and ALT cells. Both the cell
lines did not show any effect of Wi-A on telomere length
(Supplementary Figure S2) suggesting that it may alter
telomere structure or cause telomere damage/de-protection.
We hence performed quantitative assay for telomere dys-
function in control and Wi-A treated cells. The number of cells
with telomere-dysfunction-induced foci (TIF) as examined by
co-localization of γH2AX and TRF2 signals (Figure 4a)
showed significant increase (TIFs ≥4; ~ 10% to ~ 25%) in
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ALT cells (Figure 4b). In contrast, TEP cells showed no
noticeable difference in telomeric DNA damage (Figures 4a
and b).
Several studies have provided evidence that the telomere
binding proteins TRF2 and POT1 are predominantly involved
in chromosome end protection by preventing activation of a
DNA damage response.32,33 We next considered whether
Wi-A affects TRF2 and POT1. Western blotting revealed
downregulation of both these proteins in Wi-A treated
ALT cells; TEP cells possessed a low level of expression that
was not altered by Wi-A treatment (Figures 4c and d). These
data suggested that stronger cytotoxicity ofWi-A to ALT cells is
due to, at least in part, its effect on telomere protecting
proteins.
Wi- A caused downregulation of MRN complex proteins
in ALT cells. Based on the above data that Wi-A targets ALT
mechanism, we examined the status of MRN complex
proteins; essential for the ALT mechanism and APB
assembly.34,35 Western blotting revealed a sharp decline in
NBS1 and MRE11 expression and a smaller reduction of
RAD50 in Wi-A treated ALT cells. TEP cells showed only a
small/negligible change (Figures 5a and b). Of note, tumour-
derived ALT (U2OS) cells showed high level of NBS1 protein
expression that gets attenuated in response to Wi-A
treatment; TEP (MCF7) cells did not show such effect
(Supplementary Figure S1B). Real-time PCR quantitation of
their transcripts showed reduction in NBS1, but not in MRE11
and RAD50, in ALT cells. Rather, a slight increase was
observed in MRE11 and RAD50 in response to treatment
with Wi-A. TEP cells also showed a small increase in RAD50
(Figure 5c). Since MRN complex is regulated by n-Myc and
c-Myc at the transcription level,19,25 we next performed
western blotting to examine their expression in control and
Wi-A treated ALTand TEP cells. Of note, treatment with Wi-A
led to ~ 40% decrease in n-Myc and ~55% decrease in c-Myc
in JFCF-1L (ALT) cells. However, a slight increase of these
two proteins was observed in JFCF-6B (TEP) cells after the
treatment (Figure 5d).
The transcriptional activation function of Myc proteins is
regulated by their heterodimer complex formation with Max,
and the antagonistic repressor Mad-Max (the heterodimer that
competes with Myc-Max complex to bind to the identical
genomic sites and, consequently, inhibits transactivation
mediated by Myc-Max heterodimer). We next examined
Mad-1 in ALT and TEP cells following treatment with Wi-A.
Whereas the treatment did not alter Mad-1 expression in TEP
cells, there was a small decrease in ALT cells (Figure 5e). Of
Figure 1 ALT cells are sensitive to Withaferin-A (Wi-A). (a) Cell viability assays of human telomerase-plus (TEP) and -minus cells possessing Alternate mechanism of
Telomere Lengthening (ALT) showing dose-dependent cytotoxicity. ALT cells showed stronger toxicity as compared to the TEP cells both at 24 h (a) and 48 (b). Crystal Violet
staining in control and Wi-A treated cells showing stronger response of ALT cells to Wi-A treatment (c). Phase contrast images of control and Wi-A treated TEP and ALT cells;
stronger cytotoxicity and apoptosis in ALT cells were observed (d). Long-term viability assay by colony forming efficiency of control, Wi-A treated TEP and ALT cells showed
stronger response of ALT cells to the treatment (e). Quantitation from three independent experiments is shown. *Po0.05 and ***Po0.001 denote statistical significance
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note, Wi-A induced reduction in n-Myc and c-Myc proteins
(about 50%) was greater than that of Mad-1 (about 25%),
suggesting that theWi-A treated cells possessmore of Mad-1-
Max than the Myc-Max complex resulting in transcriptional
repression of the downstream effectors (such as NBS1) as
supported by data shown in Figure 5c.
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Molecular dynamic and computational insights to the
effect of Wi-A on DNA/ Myc-Max and /Mad-Max com-
plexes. We first investigated the DNA binding affinity of Myc-
Max and Mad-Max proteins. Although Myc and Mad dimerize
with the same Max protein (to form Myc-Max/Mad-Max) in
order to bind with DNA E-box via its bHLHZ domain,36 the
identity between the Myc and Mad sequences was below
28% when calculated using BLOSUM90 scoring matrix and
word size 2 of protein BLAST. It was hypothesized that
difference of residues in the DNA-binding site of Myc-Max
and Mad-Max should lead to different binding affinities with
the DNA. We tested this prediction by docking proteins with
the DNA. HADDOCK docking score of Myc-Max with DNA
was −190.6 while docking score of Mad-Max with the DNA
was − 275.1 (Table 1); suggesting that the Mad-Max protein
complex had a significantly higher binding affinity than
Myc-Max protein complex towards DNA. Higher affinity of
Mad-Max towards DNA accounted for the antagonistic nature
of Mad protein in competition with Myc protein.
We next examined the effect of Wi-A binding on Myc-Max-
DNA and Mad-Max-DNA complexes. Binding site analysis
revealed that the bHLHZ domains of Myc and Mad proteins
possess a potential ligand-binding site. Hence, residues of
DNA binding sites in both Myc-Max and Mad-Max protein
complexes were chosen as the binding site for Wi-A. Docking
poses of Wi-A revealed −5.47 kcal/mol and −5.86 kcal/mol
docking scores with Myc-Max and Mad-Max after the energy
minimization (Table 1). Upon superimposition of DNA over the
docked pose of Wi-A with Myc andMad, it was found that Wi-A
was not interfering with the DNA nucleotides, neither in Myc-
DNA complex nor in Mad-DNA complex, though the residues
were within the DNA binding region, (Figures 6a and b). These
results suggest that Wi-A is able to bind at the DNA-binding
site of Myc and Mad and does not hinder the binding of these
transcription factors to DNA.
Stability of Wi-A at the DNA binding site of Myc and Mad
proteins was revealed during the 50 ns long molecular
dynamics simulations. Root mean square deviation (RMSD)
values of Wi-A were found highly stable throughout the
simulation with Myc as well as with Mad. Simulation analysis
showed that (i) Wi-Amade highly stable complex withMad and
(ii) it also stabilized theMad-Max complexmore thanMyc-Max
complex (Figure 6c). Local interactions around Wi-A were
much stronger in Mad as compared to Myc, which explains
high stabilization of Mad-Max protein complex as compared to
Myc-Max protein complex.
Wi-A stabilized Myc-Max and Mad-Max protein complexes
were further used to check the possibility of Wi-A occupying
the DNA-binding space. For this purpose, DNA from the
crystal structure was superimposed over one of the snapshots
(protein structure) of stable trajectory of 50 ns simulation to
create protein-DNA-ligand complexes (complex between
DNA, Wi-A and Myc-Max/Mad-Max). As suggested from the
docking studies, even within stabilized protein andWi-A, it was
found that Wi-A did not interfere with any of the nucleotides of
DNA. These results suggest that Wi-A is able to stably bind at
the bHLHZ domain of Myc and Mad without interfering with
DNA binding. Further molecular dynamics simulations were
conducted to study the effect of Wi-A binding on DNA binding
affinity using the superimposed protein-DNA-ligand com-
plexes. Though backbone of both Myc and Mad proteins were
stable and did not fluctuate much during the 50 ns molecular
dynamics simulation, backbone of Mad was comparatively
more stable, showing deviation below 3.5 Å as opposed to 5 Å
of Myc-DNA complex (Figure 6c). DNA was binding with high
stability with Myc-Max and Mad-Max after the binding of Wi-A
during 50 ns simulations. Even in the presence of DNA, Wi-A
stably occupied the space in DNA-binding site without
interfering with DNA-binding in the case of both Myc-Max
and Mad-Max complexes (Figures 6d and e). Analysis of
hydrogen bonds revealed that, after the binding of Wi-A, the
number of hydrogen bonds increased during the simulations of
both Myc-Max and Mad-Max proteins (Supplementary
Figure S3). These data suggested that Wi-A actually
increases the binding affinity between the Myc-Max/Mad-
Max proteins and DNA. To further confirm this, we analysed
the total binding interface area between proteins and DNA,
before and after the binding of Wi-A. After the binding of Wi-A,
the binding interface between protein and DNA increased both
in Myc-Max/DNA and Mad-Max/DNA complexes (Table 1).
Further, the RMSD of protein-ligand-DNA complexes sug-
gested the existence of stable complex between proteins,
DNA and Wi-A.
The HADDOCK score of Mad-Max protein and DNA was
calculated to be much higher than Myc-Max and DNA, which
indicated the stronger binding of Mad with DNA as compared
to Myc. Relatively higher affinity of Mad towards DNA
enhanced further after the binding of Wi-A. For the Wi-A
-bound Mad-DNA complex, the increase in number of
hydrogen bonds as well as the binding interface between
protein and DNA was higher when compared to the Myc-DNA
complex. These data suggested that Wi-A promotes the
binding of Mad with DNA more than the binding of Myc,
thereby enhancing the repressor function of Mad-Max com-
plex against the activation of Myc-Max complex.
We next performed NBS1-promoter luciferase assay in
control and Wi-A treated cells. Two kinds of luciferase
reporters, (i) NBS1 promoter and (ii) E-box containing Myc/
Mad binding consensus sequences (Figures 7a and b) were
used to determine the effect of Wi-A on Myc/Mad-driven
Figure 2 Wi-A caused G2/M arrest and apoptosis in ALT cells. (a) Cell cycle analysis showing increase in number of ALT cells at G2 arrest with Wi-A treatment. TEP cells did
not show similar increase at equivalent dose. (b) Flow cytometric analysis showing increased apoptotic cell population with Wi-A treatment in ALT, but not TEP, cells. Quantitation
from three independent experiments is shown on the right. (c, d) Western blotting analysis for molecular markers for apoptosis in control and Wi-A treated TEP and ALT cells. The
data show cleavage of PARP-1 (c) and PARP-9 (d) in ALT, but not in TEP, cells treated with Wi-A. (e) Decrease in Procaspase-3 in Wi-A treated ALT cells. (f) p53-dependent
luciferase reporter assay showing lack of p53 wild type activity in TEP and ALT cells. U2OS cells were used as a control for wild type p53. (g) Western blot analysis of control and
Wi-A treated TEP and ALT cells showing decrease in p53, increase in p21 and decrease in Cyclin B in Wi-A treated ALT, but not TEP, cells. Quantitation from three independent
experiments is shown on the right. *Po0.05, **Po0.01 and ***Po0.001 denote statistical significance
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transcriptional regulation. As shown in Figure 7c, we found
that Wi-A caused strong suppression (~70%) of the E-box
driven luciferase reporter in two ALT cell lines. Of note, the
same reporter showed only ~ 10% decrease in Wi-A treated
TEP cell lines. Similar results were obtained in tumour-derived
cells (Figure 7d) and were also supported by decreased levels
of NBS1 protein and mRNA in Wi-A treated ALT cells
(Figures 5a− c). Furthermore, effect of Wi-A was compro-
mised in case of NBN reporter that lacked Myc/Mad binding
sites (Figures 7b and e) suggesting that Wi-A mediated
Figure 3 Wi-A caused disruption of ALT phenotype. (a) Co-immunostaining of TRF2 and PML (APB bodies) in control and Wi-A treated TEP and ALT cells showed APB
bodies only in control ALT, but not in control TEP or in either of treated, cells. Disruption of APBs was observed in Wi-A treated cells. (b) Quantitation of APB bodies in control and
Wi-A treated TEP and ALT cells from four independent experiments. (c) TRAP assay in control and Wi-A treated cells showed no effect of Wi-A on telomerase activity. (d) Neutral
comet assay in control and Wi-A treated TEP and ALT cells showing increase in DNA damage in treated ALT cells only. Quantitation from three independent experiments is shown
on the right. (e) Immunostaining of γH2AX in control and Wi-A treated TEP and ALT cells showing increase in the number of γH2AX positive cells in Wi-A treated ALT cells.
Quantitation from at least 200 cells is shown on the right. *Po0.05 and ***Po0.001 denote statistical significance
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transcriptional suppression was mediated predominantly by
binding to the Myc/Mad-sites and supported the above
computational and molecular dynamic analyses.
Discussion
Telomere shortening evokes a DNA damage response that
initiates senescence and apoptosis to avoid tumorigenesis.2,37
Cancer cells escape from telomere shortening by mechanism
(s) involving either telomerase or ALT.10,38,39 Both of these are
considered as prime drug targets for cancer therapy. More
efforts have been focused on the telomerase inhibitors due to
high incidence (80–90%) of telomerase activation as compared
to ALT (10–20%), which is most prevalent in tumours such as
astrocytomas, glioblastomas, osteosarcomas, fibrous histiocy-
tomas and liposarcomas.11,40 Recently, an ATR inhibitor,
VE-821 was shown to cause stronger DNA damage to ALT
cancer cells.41 In vitro studies have demonstrated that
telomerase and ALT mechanism can coexist within individual
cancer cells.9 Inhibition of TEP could activate ALT or vice
versa42,43 raising the need for dual action inhibitors. We report
that Wi-A is a good candidate for cancer treatment. It caused
strong cytotoxicity to ALT cells (Figures 1 and 2). Although no
effect on telomere length (Supplementary Figure S2) and
telomerase activity (Figure 3c) was observed, it kills TEP cells
by telomerase-independent mechanisms as reported
previously.30,31,44 We demonstrated that Wi-A caused strong
telomere damage in ALT cells by suppression of shelterin
proteins (TRF2 and POT1) (Figure 4). Furthermore, it caused
downregulation ofMyc and theMRNcomplex protein-NBS1, an
essential protein for ALT mechanism and cell survival.19,24,25
Zhong et al have shown that the knockdown ofNBS1 resulted in
inhibition of ALT-mediated telomere maintenance, decreased
numbers of ALT-associated PML bodies and decreased
telomere length.34
We, for the first time, demonstrate with the help of molecular
docking, computational and experimental approaches that Wi-
A inhibits Myc. Extensive molecular docking analysis of Wi-A
and Myc-Max/Mad-Max complexes revealed that (i) Wi-A
promotes the binding of Madwith DNAmore thanMyc, thereby
enhancing the antagonistic function of Mad-Max complex
against theMyc-Max complex and (ii) Wi-A stabilized theMad-
Max complex, notably more than Myc-Max complex, resulting
in its stronger binding affinity with DNA. By protein, mRNA and
reporter assays, we found that the Wi-A treated ALT cells
experience strong suppression of NBS1 protein that was
predominantly mediated by Mad/Max (Figures 5a− c and 7a).
Taken together, we report that in addition to several common
targets in TEPand ALT cancer cells (Figure 7f, shown in blue),
Wi-A targets ALT specific proteins involved in maintenance of
telomere length and hence it is considered a good candidate.
Although further studies are warranted to resolve yet other
molecular targets/mechanisms and pharmokinetics related to
stronger toxicity of Wi-A in ALT cells and tumours, it is likely
that Myc/Mad-driven suppression of NBS1 plays a major role
in this phenomenon for the reasons (i) NBS1 is upregulated in
ALT cells and is an essential survival factor for these cells.24,34
TEP cells, although equally proliferative and malignant, may
depend less on NBS1 function and (ii) transcription factor Myc
(upregulated in ALT cells), and its antagonist Mad together
Figure 4 Wi-A caused telomere dysfunction. (a) Co-immunostaining of TRF2 and γH2AX in control and Wi-A treated TEP and ALT cells showing telomere dysfunction in
ALT cells. Quantitation of the data is shown in (b). (c) Western blotting of TRF2 and POT-1 in control and Wi-A treated TEP and ALT cells showing decrease in their expression in
ALT, but not TEP, cells. β-actin was used as an internal control in all gels. Since PARP-9 and Cyclin B1 (Fig. 2) and TRF2 (c) were detected on the same blot, β-actin is same. (d)
Quantitation from three independent experiments is shown on the right. *Po0.05, **Po0.01 and ***Po0.001 denote statistical significance
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regulate NBS1 expression; Wi-A caused downregulation of
c-Myc and n-Myc. It was also predicted to increase the binding
of Mad to DNA. Collectively, these effects translated to
decrease the expression of NBS1 in ALT cells; well supported
by mRNA as well as protein analysis. Continued extensive
studies may further highlight the value of Wi-A as an effective
anticancer natural drug.
Materials and Methods
Preparation of Withaferin-A. Withaferin-A (Wi-A) was prepared from dried
Ashwagandha leaves, as described previously.44 A stock of Wi-A (10 mg/ml;
20 mM) was prepared in DMSO and stored in − 20 oC. Working concentrations of
Wi-A were prepared in cell culture medium.
Cell culture, treatments, proliferation and cell cycle assays.
Human breast carcinoma (MCF-7), melanoma (G361) and osteosarcoma (U2OS)
were obtained from Japanese Collection of Research Bioresources (JCRB, Japan).
The cells were authenticated by the source. Cells were frozen in − 80 oC and LN2 in
multiple vials and were cultured (described below) for less than 50 population
doublings for the current study. SV40-immortalized human TEP and ALT
fibroblast lines were generated from the same parental donor cell (JFCF-6), and
the details are described in Supplementary Table 1. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Grand Island, NY, USA)
and treated with Wi-A at about 60% confluency.44 Morphological observations,
crystal violet staining and cell viability (MTT and colony-forming assays) were
determined as described.45 Cell cycle and apoptosis analyses were performed
using EasyCyte Guava cytometer (Millipore, Billerica, MA, USA) and FlowJo
software (version 7.6, Flow Jo, LLC, USA) as described earlier.45 Apoptotic cells
Figure 5 Wi-A caused downregulation of MRN complex proteins. (a) Western blotting of MRN complex proteins (NBS1, Mre11 and Rad50) in control and Wi-A treated TEP
and ALT cells showing significant decrease in their expression in ALT cells. (b) Quantitation from three independent experiments is shown. (c) Real-time qRT-PCR analysis
showing decrease in NBS1 expression in Wi-A treated ALT cells was most pronounced and significant. (d) Western blotting of n-Myc, c-Myc and Mad-1 (upstream transcriptional
regulators of MRN complex proteins) in control and Wi-A treated TEP and ALT cells showing stronger decrease in their expression in the latter. (e) Quantitation from three
independent experiments is shown on the right. *Po0.05 and **Po0.01 denote statistical significance
Table 1 Docking score of Wi-A after binding with proteins at DNA binding site, HADDOCK score between protein and DNA, and change in the binding interface
between proteins and DNA after the binding of Wi-A
Myc-Max-DNA complex Mad-Max-DNA complex
Docking score −5.47 kcal/mol −5.86 kcal/mol
HADDOCK score −190.6 −275.1
Binding interface area Ligand unbound Ligand bound Ligand unbound Ligand bound
1465.5 Å2 1724 Å2 1407 Å2 2966.4 Å2
Withaferin-A kills cancer cells with or without telomerase
Y Yu et al
8
Cell Death and Disease
Figure 6 Binding of Wi-A with Myc-Max and Mad-Max complexes and its effect on structural stability. (a) Interactions of Wi-A with Myc-Max (left) and Mad-Max protein
complexes after the molecular docking. Wi-A binds at the bottom of DNA-binding site in both types of protein complexes. Docking poses of Wi-A were interacting with Myc-Max
protein complex via residues Arg911, Arg913, Arg914, Asn915, Leu917 of Myc and via residues Glu211, Arg214, Arg215, Lys219, Phe222 and Arg239 of Max protein. Interacting
residues of Mad-Max complex with Wi-A were Arg13, Arg14, Leu17, Arg18, His37, Thr38 of Mad, and Glu211, Arg214, Arg215, Phe222, and Arg239 of Max protein. (b)
Superimposition of Wi-A docked proteins with DNA bound forms to inspect the clash between Wi-A and DNA binding site. In both Myc-Max and Mad-Max, Wi-A takes place at the
empty space between arms of Myc/Mad and Max proteins, without interfering with DNA binding. (c) RMSD fluctuations of Myc-Max protein backbone (red) and Mad-Max protein
backbone (light red) during 50 ns simulation of Wi-A bound protein complexes. RMSD fluctuations of Myc-Max protein backbone (green) and Mad-Max protein backbone (light
green) during 50 ns simulation of Wi-A bound DNA-protein complexes. RMSD fluctuations of DNA in Wi-A bound Myc-Max-DNA complex (blue) and Mad-Max-DNA complex
(light blue) during 50 ns simulation. RMSD fluctuations of all three DNA, protein and ligand in Wi-A bound Myc-Max-DNA complex (purple) and Mad-Max-DNA complex (light
purple) during 50 ns simulation. (d) Depiction of stabilized Wi-A in DNA-bound bound Myc-Max after 50 ns molecular dynamics simulation. (e) Depiction of stabilized Wi-A in
DNA-bound Mad-Max proteins after 50 ns molecular dynamics simulations
Withaferin-A kills cancer cells with or without telomerase
Y Yu et al
9
Cell Death and Disease
were detected by Guava Nexin Reagent, a pre-made cocktail containing Annexin
V-PE and 7-AAD.45
Antibodies. Rabbit anti-PARP-1 (H-250), anti-caspase-3 (H-277) and anti-POT1
(H-200) (Santa Cruz, CA, USA); goat anti-PML (N-19) (Santa Cruz); mouse anti-
p53 (DO-1), anti-Cyclin B1 (GNS1), anti-N-myc (B8.4.B) and anti-TRF2 (4A794)
(Santa Cruz); rabbit anti-PARP-9, anti-PML, anti-c-Myc (Y69); mouse anti-Rad50
(13B3/2C6), anti-Mre11 (12D7) and anti-NBS1 (NBS1-501) (Abcam, Cambridge,
MA, USA); rabbit anti-phospho-histone H2A.X (20E3), anti-p21 (12D1) and
anti-Rad50 (Cell Signaling, MA, USA); mouse anti-TRF2 (Cell Signaling); mouse
anti-phospho-histone H2A.X (Millipore); rabbit anti-MAD1 (Gene Tex, CA, USA),
rabbit anti-NBS1(Novus, Cambridge, UK) and anti-beta actin (AC-15) (Abcam)
antibodies were used.
Luciferase reporter assay. PG13-luc (wt p53 binding sites), a gift from
Bert Vogelstein, and RenSP luciferase reporter construct containing the
promoter region of NBS1 (SwitchGear Genomics (Menlo Park, CA, USA),
and Myc-responsive luciferase construct encoding tandem repeats of E-box
sequence (Cignal Myc Reporter kit, Qiagen, Standford Valencia, CA, USA)
were transfected using either Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
or XtremeGENE HP (Roche, Basel, Switzerland). Luciferase activity was
detected using either a dual luciferase reporter assay system (Promega,
Madison, WI, USA) or LightSwitch Dual Assay Systems (SwitchGear
Genomics) following the manufacturer’s protocol (also detailed in Supplementary
Information).
Telomerase activity detection (TRAP assay). Telomerase activity was
determined with a PCR-based telomeric repeat amplification protocol (TRAP)
Figure 7 Wi-A caused repression of NBS-1 in ALT cells. Schematic presentation of reporters, E-box (Cignal) reporter containing Myc/Mad binding consensus sequence (a)
and NBS-1 promoter (SwitchGear) lacking the Myc/Mad binding site (b) are shown. (c) E-box reporter assays in control and Wi-A treated TEP and ALT cells showed ~ 70%
decrease in ALT, but not in TEP, cells. (d) Tumour-derived ALT (U2OS), but not the TEP (MCF7), cells also showed decrease in E-box driven luciferase reporter in Wi-A treated
cells. (e) NBS-1 promoter reporter assay on control and Wi-A treated TEP and ALT cells did not show equivalent decrease in Wi-A treated cells. Quantitation from three
independent experiments is shown. (f) A model showing the effect of Wi-A on TEP and ALT cells. It targets several cancer promoting proteins and mechanism in these cells
(shown in blue). In addition, several ALT cell-specific mechanisms (APB bodies, downregulation of NBS1 through Myc-Mad activation and induction of telomere dysfunction) are
affected causing their apoptosis. ***Po0.001 denotes statistical significance
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enzyme-linked immunosorbent assay (ELISA) kit (Roche, Mannheim, Germany)
following the manufacturer's protocol (also detailed in Supplementary Information).
Comet assay. DNA double-strand breaks were quantitated by a Comet assay
system (Trevigen, Inc, Gaithersburg, MD, USA) following the manufacturer’s
recommendations and as described earlier.45 The extent of DNA damage was
calculated as percent DNA in the tail using OpenComet (v1.3), a plugin for the
image processing program ImageJ. The study was repeated independently three
times. The data are displayed as a box and whisker diagram showing median and
middle quartiles with whiskers at the min and max.
Immunofluorescence. Control and treated cells were immunostained with
indicated antibodies as described.45 The TIF assay based on the co-localization
detection of DNA damage markers (γH2AX) and a telomeric protein (TRF1 or
TRF2) was performed as described earlier.46 Detection of APBs (by double staining
of telomeric proteins, such as TRF2, and a PML nuclear body-associated protein,
such as PML) was performed as described.47 Stained cells were examined on a
Zeiss Axiovert 200 M microscope and analysed by AxioVision 4.6 software (Carl
Zeiss, Tokyo, Japan). At least, 200 cells (on duplicate slides) were evaluated for
each treatment condition for co-localization foci counting. Three independent
experiments were performed. Images were quantified by ImageJ software (National
Institute of Health, Bethesda, MD, USA).
Western blotting. Cells were lysed with radio-immunoprecipitation assay buffer
(Thermo Scientific, Cambridge, UK) containing complete protease inhibitor cocktail
(Roche Applied Science, Mannheim, Germany). Western blotting with indicated
antibodies was performed as described earlier.45 Densitometric quantitation of the
representative immunoblots was carried out using the ImageJ software (National
Institute of Health). All experiments were performed in triplicate and at least three times.
RNA extraction and real-time qRT-PCR. Total RNA was isolated from
cells using the RNeasy mini kit (Qiagen). Equal amounts of RNA were used for
reverse transcription following the protocol of QuantiTect Rev. Transcription Kit
(Qiagen). The real-time qRT-PCR was performed on the Eco™ real time system
(Illumina, San Diego, CA, USA) using SYBR® Select Master Mix (Applied
Biosystems, Foster, CA, USA). Primers sets were listed in Supplementary Table 1.
More details were given in Supplementary Information.
Statistical analysis. The data from three or more experiments were
expressed as mean± standard deviation. Two-tailed Student’s t-test was used to
compare control and treated groups. Statistical significance was defined as
significant (*P-value≤ 0.05), very significant (**P-value≤ 0.01) and highly
significant (***P-value≤ 0.001).
Computational methods
Docking of Wi-A with Myc-Max complex and Mad-Max complex:
Structures of Myc-Max and Mad-Max protein complexes with bound DNA (PDB IDs:
1NKP and 1NLW)36 were prepared using Protein Prep Wizard of Schrödinger
software (Epik v3.3; Impact v6.8; Prime v4.1).48 The SiteMap package of the
Schrödinger software was used to identify possible ligand binding sites at Myc-Max
and Mad-Max complexes.49 Glide version 6.8 package of Schrödinger software was
used to generate the grid at the identified ligand binding site using default
parameters.50
Structure of Wi-A ligand (PubChem CID: 265237) was prepared using the LigPrep
version 3.5 module of Schrödinger software. Glide version 6.8 was used to dock Wi-A
at the identified binding site of protein complexes. Docked poses of Wi-A were
superimposed over DNA-bound protein structures to serve two purposes: first, to
check whether or not Wi-A was interfering with bound DNA, and second to generate
DNA-ligand-protein complexes. These DNA-ligand-protein complexes were later
used to study the effect of Wi-A binding on DNA binding ability of Myc-Max and Mad-
Max proteins. Docking pose visualization, superimposition of protein structures and
image generation was done using the Maestro version 10.3 Interface of the
Schrödinger software. High ambiguity-driven protein-protein DOCKing (HADDOCK)
2.2 server51 was used to dock protein complexes with DNA.
Molecular dynamics simulations: The GPU-accelerated Amber Molecular
Dynamics suite with Amber ff12SB protein force field was used to perform all atoms
explicit molecular dynamics simulations of protein-ligand and protein-DNA-ligand
complexes.52 Complex molecules were solvated with TIP3P water model in a cubic
periodic boundary box and systems were neutralized using appropriate number of
counter ions. The distance between box wall and protein complex was set to 10 Å.
Neutralized systems were then minimized, slowly and gradually heated up to 300 K
temperature, and equilibrated until the pressure and energies of systems were
stabilized. Finally, equilibrated systems were used to run 50 ns long molecular
dynamics simulations. All simulation studies were performed on DELL T3610
workstation with 16 GB DDR RAM and NVIDIA GeForce GTX TITAN Black
Graphics Card.
Analysis of molecular docking and dynamics simulations: Visual
Molecular Dynamics (VMD) version 1.9.2 was used to calculate RMSD and hydrogen
bond dynamics.53 COCOMAPS was used to calculate the total interacting area/
interface between DNA and proteins before and after the Wi-A binding.54,55 Residue
numbering of all the proteins discussed in this manuscript is according to PDB file.
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